Aethlon Medical, Inc.

Aethlon did not discuss revenue or EPS on the call. Consolidated operating expenses for the first fiscal quarter ended June 30, 2026 were approximately $1.6 million, down 11.9% from $1.8 million in the prior-year quarter. Cash and cash equivalents were approximately $4.9 million at June 30, 2026, and the company raised approximately $4 million in gross proceeds after quarter-end through a public offering of common stock. Management said current cash resources are sufficient to fund operations for at least the next 12 months. Forward-looking commentary centered on completing the Australian oncology trial by the end of calendar 2026 or early 2027, with the next earnings call expected in November 2026 alongside the fiscal second-quarter 10-Q.

Jim Frakes framed the quarter as continued execution across clinical development, platform expansion, intellectual property growth, and disciplined resource management. He emphasized that the company is advancing the Hemopurifier while controlling costs, and pointed to the move into the final oncology cohort and expanding preclinical work beyond oncology as key progress markers. His tone was cautious but constructive, repeatedly tying future progress to disciplined capital management and further data.

Frakes highlighted a relatively lean cost base, with operating expenses down 11.9% to about $1.6 million versus $1.8 million a year ago, driven by lower professional fees and reduced general and administrative and preclinical research costs. He said the company had about $4.9 million in cash and cash equivalents at quarter-end and added roughly $4 million in gross proceeds after quarter-end via a public offering. He stated that, based on current plans, the company believes it has enough cash to fund operations for at least 12 months.

Analysts focused on whether Cohort 2’s apparent biomarker effects are lasting longer than Cohort 1’s and whether that could support a future efficacy study design. LaRosa said Cohort 2 looked more consistent across participants and showed positive directional changes lasting as far out as 8 weeks in some raw-data observations, but stressed this is preliminary and not yet statistically analyzed; he said Cohort 3 will be निर्णative. On broader programs, Frakes said additional disease research can continue in-house at low cost, but clinical trials would likely need outside capital, a partner, or grants; he also mentioned possible FDA discussions about expanding breakthrough designation, but called it only a possibility.